Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura’s next generation pseudoephedrine with methamphetamine-resistant IMPEDE technology, in all Kmart in-store pharmacies nationwide (http://www.pharmacytimes.com/sap-news/Kmart-Pharmacy-Takes-Step-to-Battle-Methamphetamine).

NEXAFED launched commercially in December 2012 and is available at national and regional drug, grocery and mass merchandiser pharmacies. NEXAFED delivers the same efficacy and is priced comparably to branded immediate-release pseudoephedrine products. Acura expects to begin shipping its new NEXAFED Pressure + Pain product in January 2015. For more information about NEXAFED, please visit www.nexafed.com.

About NEXAFED NEXAFED [pseudoephedrine hydrochloride (HCl)] is a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal-congestion relief with IMPEDE technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. Specifically, the ImpedeĀ® technology forms a thick gel when the tablets are dissolved in solvents typically used in the pseudoephedrine extraction or methamphetamine production processes, trapping the pseudoephedrine or converted methamphetamine to prevent its isolation or purification.

 

 

 

 

 

 

 

 

 

 

http://money.cnn.com/news/newsfeeds/articles/marketwire/11G029123-001.htm

 

  1. KC says:

    Gosh, if Wal*Mart and all major pharmacy chains stepped up to the plate and did the right thing, it would make a good dent in the smaller DIY sector. Fingers crossed . . .